2RC

[6-({5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl}amino)-2,2-dimethyl-3-oxo-2,3-dihydro-4H-pyrido[3,2-b][1,4]oxazin-4-yl]methyl dihydrogen phosphate



Chemical Component Summary

Name[6-({5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl}amino)-2,2-dimethyl-3-oxo-2,3-dihydro-4H-pyrido[3,2-b][1,4]oxazin-4-yl]methyl dihydrogen phosphate
SynonymsFostamatinib
Identifiers[6-[[5-fluoranyl-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl]amino]-2,2-dimethyl-3-oxidanylidene-pyrido[3,2-b][1,4]oxazin-4-yl]methyl dihydrogen phosphate
FormulaC23 H26 F N6 O9 P
Molecular Weight580.46
TypeNON-POLYMER
Isomeric SMILESCC1(C(=O)N(c2c(ccc(n2)Nc3c(cnc(n3)Nc4cc(c(c(c4)OC)OC)OC)F)O1)COP(=O)(O)O)C
InChIInChI=1S/C23H26FN6O9P/c1-23(2)21(31)30(11-38-40(32,33)34)20-14(39-23)6-7-17(28-20)27-19-13(24)10-25-22(29-19)26-12-8-15(35-3)18(37-5)16(9-12)36-4/h6-10H,11H2,1-5H3,(H2,32,33,34)(H2,25,26,27,28,29)
InChIKeyGKDRMWXFWHEQQT-UHFFFAOYSA-N

Chemical Details

Formal Charge0
Atom Count66
Chiral Atom Count0
Bond Count69
Aromatic Bond Count18

Drug Info: DrugBank

DrugBank IDDB12010 
NameFostamatinib
Groups
  • approved
  • investigational
DescriptionFostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018 under the trade name Tavalisse for use in ITP [L2644,FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA [L2644].
Synonyms
  • Fostamatinib
  • Fostamatinib disodium
Brand Names
  • Tavlesse
  • Tavalisse
IndicationFostamatinib is indicated for use in the treatment of chronic immune thrombocytopenia (ITP) in patients who have had insufficient response to previous therapy [FDA Label].
Categories
  • BCRP/ABCG2 Inhibitors
  • Blood and Blood Forming Organs
  • Cytochrome P-450 CYP3A Inhibitors
  • Cytochrome P-450 CYP3A Substrates
  • Cytochrome P-450 CYP3A4 Inhibitors
ATC-CodeB02BX09
CAS number901119-35-5

Drug Targets

NameTarget SequencePharmacological ActionActions
Tyrosine-protein kinase SYKMASSGMADSANHLPFFFGNITREEAEDYLVQGGMSDGLYLLRQSRNYLGG...unknowninhibitor
Adenosine receptor A3MPNNSTALSLANVTYITMEIFIGLCAIVGNVLVICVVKLNPSLQTTTFYF...unknownantagonist
vesicular monoamine transporter 2 (VMAT2)PIIPSYLYSIKHEKNATEIQTARPVHTASISDSFQSIFSYDNSTMVTGNA...unknowninhibitor
Fatty-acid amide hydrolase 1MVQYELWAALPGASGVALACCFVAAAVALRWSGRRTARGAVVRARQRQRA...unknowninhibitor
Equilibrative nucleoside transporter 1MTTSHQPQDRYKAVWLIFFMLGLGTLLPWNFFMTATQYFTNRLDMSQNVS...unknowninhibitor
View More
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
PubChem11671467
ChEMBLCHEMBL2103830
PharosCHEMBL2103830